Author

J. M. Mesfin

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

F. White· 2 shared L. E. Stopfer· 2 shared B. A. Joughin· 1 shared B. D. Bryson· 1 shared D. A. Lauffenburger· 1 shared E. Brown· 1 shared J. A. Wells· 1 shared N. Rettko· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

F. White

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivJan 10, 2022

MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas

L. E. Stopfer, N. Rettko, O. Leddy…·F. White

This study shows MEK inhibition increases MHC-I antigen presentation in melanoma, enhancing immunotherapy efficacy through targeted epitopes.

DOI 10.1073/pnas.2208900119

humanproteomics

𝕏 PostBluesky

ImmunologybioRxivMar 3, 2020

Multiplexed relative and absolute quantitative immunopeptidomics reveals MHC I repertoire alterations induced by CDK4/6 inhibition

L. E. Stopfer, J. M. Mesfin, B. A. Joughin…·F. White

This study uses a novel immunopeptidomics approach to quantify MHC I repertoire changes induced by CDK4/6 inhibition and interferon gamma in melanoma.

DOI 10.1038/s41467-020-16588-9

humanproteomics

𝕏 PostBluesky